SLC5A2 and type 2 diabetes mellitus: Patients with T2DM were treated with metformin (81% men, 92% women), sulfonylurea (9% men, 19% women), DPP4 inhibitors (25% men, 24% women), GLP1-analogues (38% men, 43% women), SGLT2-inhibitors (29% men, 16% women) and insulin (68% men, 46% women).